Real-World Evidence Provides Insights Into the Effectiveness of Hydroxychloroquine and Tocilizumab for Treating COVID-19 – New Findings Published
COTA, in collaboration with Hackensack Meridian Health and Berry Consultants, recently conducted a study using real-world data from more than 3,000 patients hospitalized with COVID-19. The study concluded hydroxychloroquine does not improve survival for patients hospitalized with COVID-19. It was also found that another drug, tocilizumab, may improve survival among critically ill intensive care unit patients.
COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global Annual Meeting
COTA, Inc., is pleased to announce its involvement and participation in two industry leading conferences – the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and the DIA 2020 Virtual Global Annual Meeting. Collectively, the involvement at these two premier events further underscores the importance of RWD’s role in clinical research and oncology care delivery.
2020 MedTech Breakthrough Awards Recognize COTA as the Best Overall Medical Data Solution Provider
COTA, Inc. is pleased to announce that MedTech Breakthrough has named COTA as a winner in the fourth annual MedTech Breakthrough Awards program for the “Best Overall Medical Data Solution Provider” award.
COTA Participates in Reagan-Udall Foundation + Friends of Cancer Research COVID-19 Evidence Accelerator
COTA is actively participating in this collaboration, presenting key findings from ongoing research with Hackensack-Meridian Health involving observational, real-world studies of more than 3,000 hospitalized COVID-19 patients.
COTA Collaborates to Understand COVID-19 Using Real-World Evidence – New Findings Published
COTA has partnered with Hackensack Meridian Health (HMH), New Jersey’s largest and most comprehensive health network, and Berry Consultants to conduct an observational real world study of more than 3,000 hospitalized COVID-19 patients.
Dr. Ming He Joins COTA as Senior Medical Director
Today, we are excited to announce the newest addition to our team: Dr. Ming He, COTA’s Senior Medical Director. At COTA, Dr. He will work across the organization, applying her clinical oncology expertise to support various teams including abstraction operations, engineering, product, and analytics.
COTA Team Member Spotlight: Chew Lee
For our April Team Member Spotlight, we are excited to recognize Chew Lee, a Software Engineer on COTA’s engineering team. In addition to his official role as a Software Engineer, Chew also holds the position of being COTA’s Chief Celebration Officer, a role that has become increasingly important as the company adjusts to a completely remote work environment.
COTA, Inc. named a 2020 Fast 50 company by Boston Business Journal
The Boston Business Journal has named COTA, Inc. to its exclusive 2020 Fast 50 list, which represents the 50 fastest-growing private companies in Massachusetts.
Historical Regulatory Use of RWE
Historical uses of RWE in regulatory decision-making are at best sparse, but they provide the precedent on which we are building the foundation of real-world impact. This blog reviews use cases of RWE in regulatory actions.
Managing COVID-19 Among Cancer Patients: Risk & Response
New research shows that cancer patients may be more susceptible to COVID-19 than individuals without cancer, and have poorer outcomes.